Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Adaptimmune Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November... 
Tickers ADAP GSK
From GlobeNewswire News Releases
Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that new data will be presented in an oral presentation and a trial in progress poster at the... 
Tickers ADAP GSK
From GlobeNewswire News Releases
Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended September 30, 2017. 
Tickers ADAP GSK
From GlobeNewswire News Releases
Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended September 30, 2017 before the open of the U.S. markets on... 
Tickers ADAP
From GlobeNewswire News Releases
Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has joined the Company as Vice President of Communications and Investor... 
Tickers ADAP
From GlobeNewswire News Releases
James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will participate in the upcoming Leerink... 
Tickers ADAP
From GlobeNewswire News Releases
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and... 
Tickers ADAP GSK
From GlobeNewswire News Releases
Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports Second Quarter 2017 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended June 30, 2017. 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T?cells targeting NY-ESO in combination with... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE?A4 SPEAR T-cell study in patients with multiple... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Reports First Quarter 2017 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended March 31, 2017. 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl, Adaptimmune’s... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Broadens Executive Team
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin,... 
Tickers ADAP ARDX
From GlobeNewswire News Releases
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2016. 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ended December 31, 2016 before the open of... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company... 
Tickers ADAP
From GlobeNewswire News Releases
Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia
Company Officially Opens Doors to New Base for Clinical and Manufacturing Operations 
Tickers ADAP CBG LPT
From GlobeNewswire News Releases
Adaptimmune to Participate in Upcoming Investor Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6th... 
Tickers ADAP
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.